NASDAQ:XERS Xeris Biopharma - XERS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.27 -0.01 (-0.78%) (As of 03/27/2023 04:00 PM ET) Add Compare Share Share Today's Range$1.26▼$1.3150-Day Range$1.13▼$1.5352-Week Range$0.97▼$2.85Volume309,383 shsAverage Volume1.14 million shsMarket Capitalization$172.12 millionP/E RatioN/ADividend YieldN/APrice Target$5.38 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Xeris Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside319.9% Upside$5.38 Price TargetShort InterestBearish6.11% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.56) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 stars 3.5 Analyst's Opinion Consensus RatingXeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.38, Xeris Biopharma has a forecasted upside of 319.9% from its current price of $1.28.Amount of Analyst CoverageXeris Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.11% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 20.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXeris Biopharma has received a 62.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pancreatic hormones (H04)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Xeris Biopharma is -1.57. Previous Next 3.0 News and Social Media Coverage News SentimentXeris Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Xeris Biopharma this week, compared to 1 article on an average week.Search Interest40 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 122% compared to the previous 30 days.MarketBeat Follows2 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.17% of the stock of Xeris Biopharma is held by insiders.Percentage Held by InstitutionsOnly 0.12% of the stock of Xeris Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.56) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xeris Biopharma (NASDAQ:XERS) StockXeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.Read More Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Stock News HeadlinesMarch 10, 2023 | proactiveinvestors.comXeris Biopharma shares 2023 financial guidance after positive year end and fourth quarter resultsMarch 9, 2023 | finance.yahoo.comQ4 2022 Xeris Biopharma Holdings Inc Earnings CallMarch 27, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 8, 2023 | msn.comXeris stock falls ~10% despite revenue growth, narrowed loss in Q4March 8, 2023 | finance.yahoo.comXeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial GuidanceFebruary 23, 2023 | finance.yahoo.comXeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023February 2, 2023 | finance.yahoo.comXeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023January 30, 2023 | proactiveinvestors.comXeris Biopharma sees FDA grant Orphan-drug exclusivity to Recorlev for treatment of Cushing's syndromeMarch 27, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …January 30, 2023 | marketwatch.comXeris Biopharma Gets Orphan-Drug Exclusivity for RecorlevJanuary 30, 2023 | markets.businessinsider.comFDA Grants Orphan-drug Exclusivity For Xeris' Recorlev For Endogenous Cushing's Syndrome TreatmentJanuary 30, 2023 | msn.comXeris stock rises on FDA orphan drug status for hormone disorder therapy RecorlevJanuary 30, 2023 | finance.yahoo.comXeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®January 5, 2023 | finance.yahoo.comXeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2023 | finance.yahoo.comXeris Biopharma Updates Its Outlook For 2022December 31, 2022 | finance.yahoo.comA Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider increased their holdings by 16% last yearDecember 18, 2022 | proactiveinvestors.comXeris Biopharma breaks down end of year collaboration and dose-finding study updatesDecember 15, 2022 | proactiveinvestors.comXeris Biopharma to proceed with Phase II study of levothyroxine for hypothyroidismDecember 15, 2022 | finance.yahoo.comXeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for HypothyroidismNovember 28, 2022 | nasdaq.comNew Research Partnership With Horizon Therapeutics Could Be The Next Revenue Catalyst For XerisNovember 23, 2022 | proactiveinvestors.comXeris Biopharma inks research collaboration and option agreement with Horizon TherapeuticsNovember 23, 2022 | finance.yahoo.comXeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of TeprotumumabNovember 16, 2022 | finance.yahoo.comIndividual investors account for 51% of Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) ownership, while institutions account for 37%November 14, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)November 11, 2022 | proactiveinvestors.comXeris Biopharma posts record 3Q revenue as more patients utilize its treatmentsNovember 9, 2022 | apnews.comXeris Biopharma: Q3 Earnings SnapshotNovember 9, 2022 | seekingalpha.comXeris Biopharma Holdings, Inc. (XERS) Q3 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Company Calendar Last Earnings11/09/2021Today3/27/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS CUSIPN/A CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees294Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.38 High Stock Price Forecast$6.50 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+311.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net Margins-85.86% Pretax Margin-87.15% Return on Equity-135.91% Return on Assets-28.21% Debt Debt-to-Equity Ratio4.14 Current Ratio2.54 Quick Ratio2.20 Sales & Book Value Annual Sales$110.25 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book3.95Miscellaneous Outstanding Shares135,530,000Free Float128,524,000Market Cap$176.87 million OptionableNot Optionable BetaN/A Social Links Key ExecutivesPaul R. EdickChairman & Chief Executive OfficerJohn Patrick ShannonPresident & Chief Operating OfficerSteven M. PieperChief Financial OfficerSteven PrestrelskiChief Scientific OfficerKen JohnsonSenior VP-Clinical Development & Medical AffairsKey CompetitorsAC ImmuneNASDAQ:ACIULianBioNASDAQ:LIANNuvectis PharmaNASDAQ:NVCTAadi BioscienceNASDAQ:AADIOptiNoseNASDAQ:OPTNView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 45,025 shares on 3/23/2023Ownership: 0.019%Alliancebernstein L.P.Bought 15,300 shares on 2/16/2023Ownership: 0.029%IHT Wealth Management LLCSold 38,420 shares on 2/15/2023Ownership: 0.219%AQR Capital Management LLCBought 29,712 shares on 2/15/2023Ownership: 0.037%MetLife Investment Management LLCSold 45,025 shares on 2/15/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions XERS Stock - Frequently Asked Questions Should I buy or sell Xeris Biopharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XERS shares. View XERS analyst ratings or view top-rated stocks. What is Xeris Biopharma's stock price forecast for 2023? 4 brokerages have issued 12-month price targets for Xeris Biopharma's stock. Their XERS share price forecasts range from $4.00 to $6.50. On average, they anticipate the company's stock price to reach $5.38 in the next year. This suggests a possible upside of 311.9% from the stock's current price. View analysts price targets for XERS or view top-rated stocks among Wall Street analysts. How have XERS shares performed in 2023? Xeris Biopharma's stock was trading at $1.33 at the start of the year. Since then, XERS stock has decreased by 1.9% and is now trading at $1.3050. View the best growth stocks for 2023 here. Are investors shorting Xeris Biopharma? Xeris Biopharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,280,000 shares, an increase of 20.9% from the February 28th total of 6,850,000 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 7.6 days. View Xeris Biopharma's Short Interest. When is Xeris Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our XERS earnings forecast. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The firm earned $11.04 million during the quarter, compared to the consensus estimate of $10.43 million. Xeris Biopharma had a negative net margin of 85.86% and a negative trailing twelve-month return on equity of 135.91%. During the same period in the prior year, the firm posted ($0.35) earnings per share. What ETF holds Xeris Biopharma's stock ? iShares Neuroscience and Healthcare ETF holds 18,168 shares of XERS stock, representing 0.49% of its portfolio. What guidance has Xeris Biopharma issued on next quarter's earnings? Xeris Biopharma updated its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$165.00 million, compared to the consensus revenue estimate of $152.31 million. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI). When did Xeris Biopharma IPO? (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. What is Xeris Biopharma's stock symbol? Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS." Who are Xeris Biopharma's major shareholders? Xeris Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.26%), Geode Capital Management LLC (1.79%), Millennium Management LLC (0.51%), Renaissance Technologies LLC (0.37%), Deltec Asset Management LLC (0.27%) and Charles Schwab Investment Management Inc. (0.26%). Insiders that own company stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xeris Biopharma's stock price today? One share of XERS stock can currently be purchased for approximately $1.31. How much money does Xeris Biopharma make? Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $176.87 million and generates $110.25 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. How many employees does Xeris Biopharma have? The company employs 294 workers across the globe. How can I contact Xeris Biopharma? Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com. This page (NASDAQ:XERS) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.